
Jeremy D Goldhaber-Fiebert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4314498/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. New England Journal of Medicine, 2005, 353, 2158-2168.	27.0	527
2	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
3	Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. Journal of the National Cancer Institute, 2008, 100, 308-320.	6.3	199
4	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. Annals of Internal Medicine, 2012, 156, 279.	3.9	176
5	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 2105-2119.	1.6	155
6	Randomized Controlled Community-Based Nutrition and Exercise Intervention Improves Glycemia and Cardiovascular Risk Factors in Type 2 Diabetic Patients in Rural Costa Rica. Diabetes Care, 2003, 26, 24-29.	8.6	141
7	The Know-Do Gap in Quality of Health Care for Childhood Diarrhea and Pneumonia in Rural India. JAMA Pediatrics, 2015, 169, 349.	6.2	141
8	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine, 2007, 25, 6257-6270.	3.8	139
9	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	6.3	138
10	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3192-3202.	1.6	110
11	Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. International Journal of Epidemiology, 2011, 40, 417-428.	1.9	105
12	Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California. Health Affairs, 2021, 40, 870-878.	5.2	102
13	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2016, 34, 902-909.	1.6	99
14	Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC: Heart Failure, 2017, 5, 110-119.	4.1	97
15	Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression. JAMA - Journal of the American Medical Association, 2019, 321, 869.	7.4	90
16	The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review. Clinical Infectious Diseases, 2021, 73, S138-S145.	5.8	82
17	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. Annals of Internal Medicine, 2014, 161, 546.	3.9	77
18	Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Population Health Metrics, 2007, 5, 11.	2.7	74

#	Article	IF	CITATIONS
19	Diabetes, Its Treatment, and Catastrophic Medical Spending in 35 Developing Countries. Diabetes Care, 2012, 35, 319-326.	8.6	74
20	Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring inÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 368-375.	4.1	74
21	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	6.3	69
22	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 926.	6.1	65
23	Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine, 2006, 24, S155-S163.	3.8	64
24	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. PLoS ONE, 2013, 8, e58975.	2.5	61
25	Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology, 2019, 4, 128.	6.1	61
26	Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980-1997. Globalization and Health, 2011, 7, 45.	4.9	58
27	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Annals of Internal Medicine, 2013, 159, 382.	3.9	56
28	Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. PLoS Medicine, 2017, 14, e1002312.	8.4	53
29	Trade-offs in Cervical Cancer Prevention. Archives of Internal Medicine, 2008, 168, 1881.	3.8	52
30	Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report. Value in Health, 2021, 24, 463-472.	0.3	52
31	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020, 23, 734-742.	0.3	51
32	Exploration and adoption of evidence-based practice by US child welfare agencies. Children and Youth Services Review, 2014, 39, 147-152.	1.9	50
33	Cost-effectiveness of Intensive Blood Pressure Management. JAMA Cardiology, 2016, 1, 872.	6.1	48
34	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. Journal of the American College of Cardiology, 2013, 61, 1250-1258.	2.8	47
35	The Business Case for Quality Improvement. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 416-424.	2.2	45
36	Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ, The, 2013, 347, f6048-f6048.	6.0	45

#	Article	IF	CITATIONS
37	Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Annals of Internal Medicine, 2016, 165, 10.	3.9	45
38	Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry, 2021, 78, 767.	11.0	45
39	Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis. PLoS Medicine, 2012, 9, e1001348.	8.4	44
40	Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. PLoS Medicine, 2018, 15, e1002532.	8.4	44
41	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. Medical Decision Making, 2015, 35, 584-595.	2.4	43
42	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	2.5	41
43	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Advances, 2018, 2, 1946-1956.	5.2	40
44	Evaluation of Emergency Department Pediatric Readiness and Outcomes Among US Trauma Centers. JAMA Pediatrics, 2021, 175, 947.	6.2	40
45	Quantifying and Benchmarking Disparities in COVID-19 Vaccination Rates by Race and Ethnicity. JAMA Network Open, 2021, 4, e2130343.	5.9	39
46	The costs of reducing loss to follow-up in South African cervical cancer screening. Cost Effectiveness and Resource Allocation, 2005, 3, 11.	1.5	37
47	Covid-19 Vaccine Acceptance in California State Prisons. New England Journal of Medicine, 2021, 385, 374-376.	27.0	37
48	COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. Journal of General Internal Medicine, 2021, 36, 3096-3102.	2.6	37
49	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology, 2017, 283, 460-468.	7.3	36
50	The Utility of Childhood and Adolescent Obesity Assessment in Relation to Adult Health. Medical Decision Making, 2013, 33, 163-175.	2.4	35
51	Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial. Contemporary Clinical Trials, 2015, 43, 260-278.	1.8	35
52	Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies. Lancet Public Health, The, 2021, 6, e760-e770.	10.0	35
53	Estimating the cost of cervical cancer screening in five developing countries. Cost Effectiveness and Resource Allocation, 2006, 4, 13.	1.5	34
54	Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. New England Journal of Medicine, 2021, 385, 2300-2301.	27.0	31

#	Article	IF	CITATIONS
55	Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. Annals of Internal Medicine, 2020, 172, 248.	3.9	30
56	Economic evaluation research in the context of Child Welfare policy: A structured literature review and recommendations. Child Abuse and Neglect, 2011, 35, 722-740.	2.6	28
57	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making, 2020, 40, 314-326.	2.4	28
58	Evaluation of a social franchising and telemedicine programme and the care provided for childhood diarrhoea and pneumonia, Bihar, India. Bulletin of the World Health Organization, 2017, 95, 343-352E.	3.3	27
59	Population Health and Cost-Effectiveness Implications of a "Treat All―Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy and Practice, 2018, 3, 238146831877663.	0.9	26
60	Effect Of A Large-Scale Social Franchising And Telemedicine Program On Childhood Diarrhea And Pneumonia Outcomes In India. Health Affairs, 2016, 35, 1800-1809.	5.2	25
61	Empirically Evaluating Decision-Analytic Models. Value in Health, 2010, 13, 667-674.	0.3	24
62	Disease Control Implications of India's Changing Multi-Drug Resistant Tuberculosis Epidemic. PLoS ONE, 2014, 9, e89822.	2.5	24
63	Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India's public care system covering >100,000,000 inhabitants. BMC Public Health, 2014, 14, 418.	2.9	24
64	Program Spending to Increase Adherence: South African Cervical Cancer Screening. PLoS ONE, 2009, 4, e5691.	2.5	23
65	Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Annals of Internal Medicine, 2015, 163, 417-426.	3.9	23
66	Association of Emergency Department Pediatric Readiness With Mortality to 1 Year Among Injured Children Treated at Trauma Centers. JAMA Surgery, 2022, 157, e217419.	4.3	23
67	Quantifying Child Mortality Reductions Related to Measles Vaccination. PLoS ONE, 2010, 5, e13842.	2.5	21
68	Some Health States Are Better Than Others. Medical Decision Making, 2016, 36, 927-940.	2.4	18
69	Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. Clinical Infectious Diseases, 2020, 71, 3136-3143.	5.8	17
70	Nationwide cost-effectiveness analysis of surgical stabilization of rib fractures by flail chest status and age groups. Journal of Trauma and Acute Care Surgery, 2021, 90, 451-458.	2.1	16
71	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e838-e845.	5.8	16
72	Analyzing Screening Policies for Childhood Obesity. Management Science, 2013, 59, 782-795.	4.1	15

#	Article	IF	CITATIONS
73	What Is the Optimal Primary Care Panel Size?. Annals of Internal Medicine, 2020, 172, 195.	3.9	15
74	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. Journal of General Internal Medicine, 2022, 37, 3380-3387.	2.6	15
75	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Management Science, 2017, 20, 16-32.	2.6	14
76	Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Health Care Management Science, 2018, 21, 632-646.	2.6	14
77	Evaluating Child Welfare Policies with Decision-Analytic Simulation Models. Administration and Policy in Mental Health and Mental Health Services Research, 2012, 39, 466-477.	2.1	13
78	Profiles of sociodemographic, behavioral, clinical and psychosocial characteristics among primary care patients with comorbid obesity and depression. Preventive Medicine Reports, 2017, 8, 42-50.	1.8	13
79	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver–kidney Transplant as a Case Example. Transplantation, 2020, 104, 387-394.	1.0	13
80	Uptake of COVID-19 Vaccination Among Frontline Workers in California State Prisons. JAMA Health Forum, 2022, 3, e220099.	2.2	13
81	Providers' knowledge of diagnosis and treatment of tuberculosis using vignettes: evidence from rural Bihar, India. BMJ Clobal Health, 2016, 1, e000155.	4.7	12
82	School Reopenings and the Community During the COVID-19 Pandemic. JAMA Health Forum, 2020, 1, e201294.	2.2	11
83	Prioritizing Guideline-Recommended Interventions. Annals of Internal Medicine, 2013, 159, 223.	3.9	10
84	Assessing Screening Policies for Childhood Obesity. Obesity, 2012, 20, 1437-1443.	3.0	9
85	Comparing Simultaneous Liver-Kidney Transplant Strategies. Transplantation, 2018, 102, e219-e228.	1.0	9
86	Effect of an Intervention for Obesity and Depression on Patient-Centered Outcomes: An RCT. American Journal of Preventive Medicine, 2020, 58, 496-505.	3.0	9
87	Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. Journal of Infectious Diseases, 2021, 224, S612-S624.	4.0	9
88	RCT of the effectiveness of stepped-care sleep therapy in general practice: The RESTING study protocol. Contemporary Clinical Trials, 2022, 116, 106749.	1.8	9
89	Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value in Health, 2018, 21, 921-930.	0.3	8
90	Costâ€effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. Otolaryngology - Head and Neck Surgery, 2019, 161, 82-90.	1.9	8

#	Article	IF	CITATIONS
91	Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. Addiction, 2021, 116, 3494-3503.	3.3	8
92	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM Policy and Practice, 2016, 1, 238146831667194.	0.9	7
93	An Efficient, Noniterative Method of Identifying the Cost-Effectiveness Frontier. Medical Decision Making, 2016, 36, 132-136.	2.4	7
94	Methods for Model Calibration under High Uncertainty: Modeling Cholera in Bangladesh. Medical Decision Making, 2020, 40, 693-709.	2.4	7
95	Optimal patient selection for simultaneous heart-kidney transplant: A modified cost-effectiveness analysis. American Journal of Transplantation, 2022, 22, 1158-1168.	4.7	7
96	Explaining variations in state foster care maintenance rates and the implications for implementing new evidence-based programs. Children and Youth Services Review, 2014, 39, 183-206.	1.9	6
97	Modeling and Calibration for Exposure to Time-Varying, Modifiable Risk Factors. Medical Decision Making, 2015, 35, 196-210.	2.4	6
98	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. Medical Decision Making, 2018, 38, 849-865.	2.4	6
99	Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis. MDM Policy and Practice, 2019, 4, 238146831986644.	0.9	6
100	Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar. Tropical Medicine and Infectious Disease, 2021, 6, 101.	2.3	6
101	Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. Medical Decision Making, 2022, 42, 143-155.	2.4	6
102	Risk stratification in compartmental epidemic models: Where to draw the line?. Journal of Theoretical Biology, 2017, 428, 1-17.	1.7	5
103	First‥ear Economic and Quality of Life Effects of the RAINBOW Intervention to Treat Comorbid Obesity and Depression. Obesity, 2020, 28, 1031-1039.	3.0	5
104	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. International Journal of Drug Policy, 2021, 88, 102726.	3.3	5
105	Religion and Sanitation Practices. World Bank Economic Review, 2021, 35, 287-302.	2.4	5
106	Using RE-AIM to examine the potential public health impact of an integrated collaborative care intervention for weight and depression management in primary care: Results from the RAINBOW trial. PLoS ONE, 2021, 16, e0248339.	2.5	5
107	Quantifying Positive Health Externalities of Disease Control Interventions: Modeling Chikungunya and Dengue. Medical Decision Making, 2019, 39, 1045-1058.	2.4	4
108	Quantifying demographic and socioeconomic transitions for computational epidemiology: an open-source modeling approach applied to India. Population Health Metrics, 2015, 13, 19.	2.7	3

#	Article	IF	CITATIONS
109	Will Divestment from Employmentâ€Based Health Insurance Save Employers Money? The Case of State and Local Governments. Journal of Empirical Legal Studies, 2015, 12, 343-394.	0.8	3
110	Optimal Information Collection Policies in a Markov Decision Process Framework. Medical Decision Making, 2018, 38, 797-809.	2.4	3
111	Mapping Inequality in SARS-CoV-2 Household Exposure and Transmission Risk in the USA. Journal of General Internal Medicine, 2021, 36, 1476-1478.	2.6	3
112	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1200-1209.	4.9	3
113	Prevention and control of dengue and chikungunya in Colombia: A cost-effectiveness analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0010086.	3.0	3
114	The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Applied Health Economics and Health Policy, 2019, 17, 513-521.	2.1	2
115	How does information on the harms and benefits of cervical cancer screening alter the intention to be screened?: a randomized survey of Norwegian women. European Journal of Cancer Prevention, 2019, 28, 87-95.	1.3	2
116	Optimal Allocation of Research Funds under a Budget Constraint. Medical Decision Making, 2020, 40, 797-814.	2.4	2
117	Patterns of heavy drinking behaviour over age and birth cohorts among Chinese men: a Markov model. BMJ Open, 2021, 11, e043261.	1.9	2
118	Predicting the Effectiveness of Endemic Infectious Disease Control Interventions: The Impact of Mass Action versus Network Model Structure. Medical Decision Making, 2021, 41, 623-640.	2.4	2
119	Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. JAMA Network Open, 2021, 4, e2113969.	5.9	2
120	Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study. MDM Policy and Practice, 2021, 6, 238146832110492.	0.9	2
121	Male involvement in cardiovascular preventive healthcare in two rural Costa Rican communities. Preventive Medicine, 2005, 40, 690-695.	3.4	1
122	Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs. Medical Decision Making, 2020, 40, 978-989.	2.4	1
123	Assessing Interventions That Prevent Multiple Infectious Diseases: Simple Methods for Multidisease Modeling. Medical Decision Making, 2022, 42, 436-449.	2.4	1
124	Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, e007993.	2.2	1
125	Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer. Journal of Urology, 2022, 208, 80-89.	0.4	1
126	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Annals of Internal Medicine, 2014, 160, 143.	3.9	0

#	Article	IF	CITATIONS
127	New, Expensive Treatments for Chronic Hepatitis C: Insuring Good Outcomes?. Digestive Diseases and Sciences, 2015, 60, 3153-3154.	2.3	0
128	Cost-effectiveness of Intensive Blood Pressure Management—Is There an Additional Price to Pay?—Reply. JAMA Cardiology, 2017, 2, 581.	6.1	0
129	Biomedical Decision Making: Probabilistic Clinical Reasoning. , 2021, , 77-120.		Ο
130	Health Disparities And COVID-19: The Authors Reply. Health Affairs, 2021, 40, 1514-1514.	5.2	0
131	Author Response to "Optimal Sample Size Calculation for Clinical Research under a Budget Constraint― Medical Decision Making, 2022, 42, 419-420.	2.4	0